Please wait while we load the price list

Business Wire - Verispan Announces: 1.1 Million Patients Filled Prescriptions for Diovan HCT in the 2nd Quarter of 2004

November 17th, 2008

YARDLEY, Pa. — According to traditional total prescription (TRx) metrics, there were 2.3 million prescriptions for Diovan HCT in the second quarter of 2004. However, Verispan’s Total Patient Tracker, which measures market sizes by viewing unique patients, shows the actual number of patients who filled prescriptions for the hypertension drug during the same time period was 1.1 million–less than half the number of prescriptio…

Business Wire - Research and Markets: New Report Predicts that Novartis’ Diovan, Glivec/Gleevec and Zelmac/Zelnorm will Continue to Show Healthy Sales Growth

November 11th, 2008

DUBLIN, Ireland — Research and Markets (http://www.researchandmarkets.com/reports/c64756) has announced the addition of Novartis: Performance, Products, Pipeline and Potential to their offering.
Pharmaceutical company intelligence reports provide a ful…

JCNN News Summaries - Japan Corporate News Network - Novartis Pharma Adds High-Dose Tablet to Its Antihypertensive

November 8th, 2008

The following untitled letters were issued by Center for Food Safety and Nutrition’s (CFSAN) Division of Dietary Supplement Programs Office of Nutritional Products or by Center for Drug Evaluation and Research’s Office of Medical Policy Division of Drug …

PR Newswire - Single-Pill Combinations Diovan HCT and Exforge Approved in US as First-Line Treatments for High Blood Pressure

November 6th, 2008

- Approvals consistent with current US treatment guidelines to start appropriate patients on combination therapies
- Up to 80% of patients may need multiple medications to help them reach blood pressure goals
- Single-pill combinations offer effective, convenient medications which could help patients reach treatment goals faster
- Diovan HCT and Exforge approvals may benefit patients who are likely to…

Canadian Corporate News - [0] Landmark trial demonstrates that Diovan(R) (valsartan) significantly reduces combined all-cause mortality and morbidity in patients with heart, failure@…

November 5th, 2008

Atacand
(candesartan, AstraZeneca)

Most Popular
10 Jobs That Pay $30 An Hour
5 Regular Mistakes In Public Speaking
Today’s Best Part-Time Jobs
3 Questions No Job Seeker Ever Wants To Be Asked?
13 Job Interview Mistakes To Avoid

An angiotensin receptor blocker (ARB) for treating patients with heart failure (NYHA class II-IV and an ejection fraction of 40% or less), to reduce the risk of death from ca…

Advertising Age - Life afterJack: The unlikely tale of Hill Holliday’s comeback.(News)

October 31st, 2008

Byline: RUPAL PAREKH And MATTHEW CREAMER
rparekh@adage.com, mcreamer@adage.com

Related Results

Pharma Marketletter - Novartis’ Diovan as effective as Norvasc in hypertensive patients with high CVD risk.

October 28th, 2008

Results have been published in The Lancet from the eagerly-awaited VALUE (Valsartan Antihypertensive Long-term Use Evaluation) trial, which compared Novartis’ angiotensin II receptor blocker Diovan (valsartan) with Pfizer’s calcium antagonist Norvasc (amlodipine) in hypertensive patients at high cardiovascular risk.

Most Popular
3 Questions No Job Seeker Ever Wants T…

HealthDay - Two Drugs for Heart Failure Show Mixed Results

October 23rd, 2008

Two new studies have produced mixed results for two different drugs that are often used to treat heart failure.
In the first study, researchers found limited benefit from a drug called valsartan (Diovan), which is used to lower systolic bloo…

OB/GYN News - Diovan

October 20th, 2008

(valsartan, Novartis)
An angiotensin receptor blocker (ARB) for treating heart failure (New York Heart Association class II-IV) in people who cannot tolerate ACE inhibitors. The first ARB approved for heart fa…

Market Wire - Diovan(R) (Valsartan) the First Blood Pressure Medication in a Large-Scale Clinical Trial to Lower C-Reactive Protein, an Important Marker of Inflammation

October 16th, 2008

Diovan lowered the level of the inflammatory
marker high sensitivity C-reactive protein (hsCRP), independently of its
established efficacy in lowering blood pressure, according to findings
presented at the American Society of Hypertension, Inc. (ASH) Annual
Scientific Meeting and Exposition (ASH 2006) and published online in
Hypertension later today. The study also showed that Diovan and Diovan HCT
helped a significant number of hard-to-treat patients with a severe for…